Company intelligence / Profile preview
Guangzhou Yinnuo Pharmaceutical
Guangzhou, Guangdong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangzhou Yinnuo Pharmaceutical is a leading GLP-1 company in Asia, with its core recombinant protein product efsubaglutide alfa (InnoLight) approved in China for type 2 diabetes in 2025. Programs in obesity and MASH have reached global Phase 2/3; further pipeline includes early-stage biologics across metabolic, immune, and neuroscience indications.
- Therapeutic areas
- OncologyNeurologyEndocrinologyMetabolic Disorders
- Modalities
- Recombinant proteinFc fusion proteinFusion protein
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
CITIC Securities (IPO sponsor)CICC (IPO sponsor)
Beyond the preview
Go deeper on Guangzhou Yinnuo Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Yinnuo Pharmaceutical.